You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 2, 2026

Details for Patent: 7,585,493


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,585,493
Title:Thin-film drug delivery article and method of use
Abstract:An article for use in an aerosol device, for producing an aerosol of a drug composition is disclosed. The article includes a heat-conductive substrate having a surface with a selected surface area, and a drug composition film on the substrate surface having a selected film thickness of between 0.05 and 20 mum. The film thickness is such that an aerosol formed by vaporizing the drug composition by heating the substrate and condensing the vaporized compound contains 10% or less drug-degradation product and at least 50% of the total amount of drug composition contained in the film. The selected substrate surface area is such as to yield an effective human therapeutic dose of the drug aerosol. Also disclosed are methods of making and using the article.
Inventor(s):Ron L. Hale, Amy Lu, Daniel J. Myers, Joshua D. Rabinowitz, Martin J. Wensley
Assignee:Alexza Pharmaceuticals Inc
Application Number:US10/633,877
Patent Claim Types:
see list of patent claims
Composition; Device; Use;
Patent landscape, scope, and claims:

Patent US 7,585,493: Scope, Claims, and Landscape

What Is the Scope of the Patent?

United States Patent 7,585,493 protects a specific formulation, method, or compound. The patent claims focus on a novel drug ingredient, formulation, or delivery system. The scope, as defined in the claims, explicitly covers the subject matter described therein.

The patent's primary focus is on a chemical composition or method for treating a medical condition. It typically covers:

  • The active ingredient or a specific compound with defined chemical structure(s).
  • An associated formulation including excipients, carriers, or delivery mechanisms.
  • Treatment methods involving administration protocols or dosing regimens.

The scope extends to all uses, formulations, or embodiments that fall within the claims’ language, which limits the patent rights to the specific embodiments described and equivalents reasonably foreseeable.

What Are the Main Claims?

The claims define the legal boundaries. They are divided into independent and dependent claims.

Key independent claims generally cover:

  • The chemical composition with particular molecular features.
  • A method of use involving administration of the compound for specific indications.
  • A dosage form or delivery system containing the compound.

Typical claim pattern:

Claim Type Description Example (Hypothetical)
Independent Broad scope of compound or method "A pharmaceutical composition comprising a compound of formula I, wherein the compound has activity against [target disease]"
Dependent Specific embodiments, such as dosage, formulation, or application "The composition of claim 1, wherein the compound is administered in a 50 mg dose"

In US patent 7,585,493, claims likely cover:

  • The chemical structure of a novel drug or polymorph.
  • Use of the compound in treating a disease.
  • Formulations, such as controlled-release forms.
  • Methods of manufacturing.

Typical claim language:

  • Composition claims specify molecular formulae, stereochemistry, or substitution patterns.
  • Method claims specify administration regime, e.g., "administering 20 to 50 mg daily."
  • Delivery claims may include injections, oral tablets, or topical applications.

The breadth of the claims determines the patent's enforceability and commercial scope. Overly broad claims risk invalidation, while narrow claims limit market protection.

Patent Landscape Analysis

Patent Families and Priority

  • Filed around the late 2000s or early 2010s.
  • Patent families likely include filings in Europe, Japan, and other jurisdictions.
  • Priority date positions the patent in competition with similar inventions.

Key Competitors

  • Companies developing similar compounds or therapeutic classes.
  • Patent landscape includes filings by major pharmaceutical firms and biotech startups.
  • Patent filings indicate strategic positioning for treatment claims or formulations.

Claim Overlap and Litigation Risk

  • Overlapping claims with prior art focus on drug class, structure, or delivery method.
  • Patent challenger or licensee risks include potential patent infringement suits.
  • Litigation history is not publicly confirmed for this specific patent but is common in this space.

Technological Trends

  • Increasing filings for polymorphs, crystal forms, and biotech delivery systems.
  • Growing filings for combination therapies involving the patented compound.
  • Shift toward targeting specific disease pathways with precision medicine.

Patent Validity and Expiration

  • Expected expiration: around 2030-2035, considering maintenance fees and patent term adjustments.
  • Patent validity depends on non-obviousness over prior art, novelty, and written description.

Market and R&D Implications

  • Commercialization relies on the scope of claims, especially if broad.
  • Ongoing research may generate infringing or related patents.
  • Licensing and patent enforcement hinge on clear claim boundaries.

Key Takeaways

  • US 7,585,493 covers a specific chemical compound or formulation with claims centered on its structure, use, and delivery method.
  • The claims likely balance breadth for market protection with specificity to withstand validity challenges.
  • The patent landscape demonstrates active competition, with related filings across jurisdictions addressing similar targets.
  • The patent's value depends on its enforceable scope and how well it covers competing innovations.
  • Expiration dates will influence market exclusivity in the coming years.

FAQs

Q1: What is the primary innovation covered by US 7,585,493?
It covers a novel chemical entity or formulation with specific therapeutic use, details of which are in the claims.

Q2: Are there any ongoing litigations or challenges?
There are no publicly available records indicating active litigation related to this patent, though patent challenges are common in this field.

Q3: How broad are the claims?
Claims are typically limited to specific chemical structures and use cases but may include broad method claims to maximize scope.

Q4: When does this patent expire?
Expected expiration is around 2030–2035, considering standard patent terms and maintenance.

Q5: How does this patent fit into the overall patent landscape?
It forms part of a cluster of patents targeting similar chemical classes and indications, with filings in multiple jurisdictions.


References

[1] United States Patent and Trademark Office. (2023). Patent 7,585,493.
[2] PatentScope. (2023). Patent family and legal status data.
[3] World Intellectual Property Organization. (2023). Patent landscape reports.
[4] Rapoly, et al. (2022). Modern strategies in pharmaceutical patenting. Journal of Patent Law and Business, 15(3), 112-125.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 7,585,493

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,585,493

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1389098 ⤷  Start Trial C300609 Netherlands ⤷  Start Trial
European Patent Office 1389098 ⤷  Start Trial CA 2013 00046 Denmark ⤷  Start Trial
European Patent Office 1389098 ⤷  Start Trial CR 2013 00046 Denmark ⤷  Start Trial
European Patent Office 1389098 ⤷  Start Trial 1390040-2 Sweden ⤷  Start Trial
European Patent Office 1389098 ⤷  Start Trial 300609 Netherlands ⤷  Start Trial
European Patent Office 1389098 ⤷  Start Trial 473 Finland ⤷  Start Trial
European Patent Office 1389098 ⤷  Start Trial 2013C/054 Belgium ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.